Sevoflurane vs. propofol in patients with coronary disease undergoing mitral surgery: A randomised study

Acta Anaesthesiologica Scandinavica

Volumn 56, Issue 4, 2012, Pages 482-490

  Bignami, E ^a   Landoni, G ^a,b,c   Gerli, C ^a   Testa, V ^a   Mizzi, A ^a   Fano, G ^a   Nuzzi, M ^a   Franco, A ^a   Zangrillo, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b OUTCOMES RESEARCH CONSORTIUM   (United States)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; PROPOFOL; SEVOFLURANE; TROPONIN;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; FORWARD HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

AGED; ANESTHETICS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; METHYL ETHERS; MIDDLE AGED; MITRAL VALVE; PROPOFOL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TROPONIN;

EID: 84858702456     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2011.02570.x     Document Type: Article

References (40)

1. De Hert SG, Turani F, Mathur S, Stowe DF,. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg 2005; 100: 1584-1593.
2. Chiari P, Bouvet F, Piriou V,. Anaesthetic-induced myocardial preconditioning: fundamental basis and clinical implications. Ann Fr Anesth Reanim 2005; 24: 383-396.
3. De Hert SG,. The concept of anaesthetic-induced cardioprotection: clinical relevance. Best Pract Res Clin Anaesthesiol 2005; 19: 445-459.
4. Symons JA, Myles PS,. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006; 97: 127-136.
5. Yu CH, Beattie WS,. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can J Anaesth 2006; 53: 906-918.
6. Landoni G, Biondi-Zoccai GG, Zangrillo A, Bignami E, DAvolio S, Marchetti C, Calabrè MG, Fochi O, Guarracino F, Tritapepe L, De Hert S, Torri G,. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007; 21: 502-511.
7. Bignami E, Landoni G, Crescenzi G, Gonfalini M, Bruno G, Pappalardo F, Marino G, Zangrillo A, Alfieri O,. Role of cardiac biomarkers (troponin I and CK-MB) as predictors of quality of life and long-term outcome after cardiac surgery. Ann Card Anaesth 2009; 12: 22-26.
8. Landoni G, Bignami E, Oliviero F, Zangrillo A,. Halogenated anaesthetics and cardiac protection in cardiac and non-cardiac anaesthesia. Ann Card Anaesth 2009; 12: 4-9.
9. Landoni G, Fochi O, Tritapepe L, Guarracino F, Belloni I, Bignami E, Zangrillo A,. Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009; 75: 269-273.
10. De Hert SG, Van der Linden PJ, Cromheecke S, Meeus R, Nelis A, Van Reeth V, ten Broecke PW, De Blier IG, Stockman BA, Rodrigus IE,. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101: 299-310.
11. De Hert S, Vlasselaers D, Barbé R, Ory JP, Dekegel D, Donnadonni R, Demeere JL, Mulier J, Wouters P,. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009; 64: 953-960.
12. Story DA, Poustie S, Liu G, McNicol PL,. Changes in plasma creatinine concentration after cardiac anesthesia with isoflurane, propofol, or sevoflurane: a randomized clinical trial. Anesthesiology 2001; 95: 842-848.
13. Tritapepe L, Landoni G, Guarracino F, Pompei F, Crivellari M, Maselli D, De Luca M, Fochi O, DAvolio S, Bignami E, Calabrè MG, Zangrillo A,. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 2007; 24: 323-331.
14. Bein B, Renner J, Caliebe D, Scholz J, Paris A, Fraund S, Zaehle W, Tonner PH,. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100: 610-616.
15. Conzen PF, Fischer S, Detter C, Peter K,. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 2003; 99: 826-833.
16. Guarracino F, Landoni G, Tritapepe L, Pompei F, Leoni A, Aletti G, Scandroglio AM, Maselli D, De Luca M, Marchetti C, Crescenzi G, Zangrillo A,. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006; 20: 477-483.
17. Landoni G, Calabrè MG, Marchetti C, Bignami E, Scandroglio AM, Dedola E, De Luca M, Tritapepe L, Crescenzi G, Zangrillo A,. Desflurane versus propofol in patients undergoing mitral valve surgery. J Cardiothorac Vasc Anesth 2007; 21: 672-677.
18. Cromheecke S, Pepermans V, Hendrickx E, Lorsomradee S, Ten Broecke PW, Stockman BA, Rodrigus IE, De Hert SG,. Cardioprotective properties of sevoflurane in patients undergoing aortic valve replacement with cardiopulmonary bypass. Anesth Analg 2006; 103: 289-296.
19. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW,. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007; 50: 1707-1732.
20. Landoni G, Fochi O, Bignami E, Calabrè MG, DArpa MC, Moizo E, Mizzi A, Pappalardo F, Morelli A, Zangrillo A,. Cardiac protection by volatile anesthetics in non-cardiac surgery? A meta-analysis of randomized controlled studies on clinically relevant endpoints. HSR Proc Intensive Care Cardiovasc Anesth 2009; 4: 34-43.
21. Landoni G, Zangrillo A, Fochi O, Maj G, Scandroglio AM, Morelli A, Tritapepe L, Montorfano M, Colombo A,. Cardiac protection with volatile anesthetics in stenting procedures. J Cardiothorac Vasc Anesth 2008; 22: 543-547.
22. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E,. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007; 21: 664-671.
23. Lamberts RR, Onderwater G, Hamdani N, Vreden MJ, Steenhuisen J, Eringa EC, Loer SA, Stienen GJ, Bouwman RA,. Reactive oxygen species-induced stimulation of 5AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation 2009; 120: S10-15.
24. Landoni G, Fochi O, Bignami E, De Simone F, Zangrillo A,. Volatile anesthetics for periprocedural cardiac protection. A review. Minerva Cardioangiol 2008; 56: 429-434.
25. Thygesen K, Alpert JS, White HD,. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: consensus conference for the universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
26. Murry CE, Jennings RB, Reimer KA,. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-1136.
27. Yao Y-T, Li L-H,. Sevoflurane versus propofol for myocardial protection in patients undergoing coronary artery bypass grafting surgery: a meta-analysis of randomized controlled trials. Chin Med Sci J 2009; 24: 133-141.
28. Bignami E, Biondi-Zoccai G, Landoni G, Fochi O, Testa V, Sheiban I, Giunta F, Zangrillo A,. Volatile anesthetics reduce mortality in cardiac surgery. J Cardiothorac Vasc Anesth 2009; 23: 594-599.
29. Landoni G, Augoustides JG, Guarracino F, Santini F, Ponschab M, Pasero D, Rodseth RN, Biondi-Zoccai G, Silvay G, Salvi L, Camporesi E, Comis M, Conte M, Bevilacqua S, Cabrini L, Cariello C, Caramelli F, De Santis V, Del Sarto P, Dini D, Forti A, Galdieri N, Giordano G, Gottin L, Greco M, Maglioni E, Mantovani L, Manzato A, Meli M, Paternoster G, Pittarello D, Rana KN, Ruggeri L, Salandin V, Sangalli F, Zambon M, Zucchetti M, Bignami E, Alfieri O, Zangrillo A,. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference. Acta Anaesthesiol Scand 2011; 55: 259-266.
30. Landoni G, Augoustides JG, Guarracino F, Santini F, Ponschab M, Pasero D, Rodseth RN, Biondi-Zoccai G, Silvay G, Salvi L, Camporesi E, Comis M, Conte M, Bevilacqua S, Cabrini L, Cariello C, Caramelli F, De Santis V, Del Sarto P, Dini D, Forti A, Galdieri N, Giordano G, Gottin L, Greco M, Maglioni E, Mantovani L, Manzato A, Meli M, Paternoster G, Pittarello D, Rana KN, Ruggeri L, Salandin V, Sangalli F, Zambon M, Zucchetti M, Bignami E, Alfieri O, Zangrillo A,. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference. HSR proceedings in intensive care and cardiovascular anesthesia. 2011; 3: 9-19.
31. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA,. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95: 125-134.
32. Larsen JR, Smerup M, Hasenkam JM, Christensen SD, Sivesgaard K, Torp P, Sloth E,. Hypertrophied hearts: what of sevoflurane cardioprotection? Acta Anaesthesiol Scand 2009; 53: 496-504.
33. Pesonen E,. Editorial: cardiac pre- and post-conditioning: implications in anesthesia? Acta Anaesthesiol Scand 2010; 54: 793-794.
34. Zaugg M,. Is protection by inhalation agents volatile? Controversies in cardioprotection. Br J Anaesth 2007; 99: 603-606.
35. Mio Y, Bienengraeber MW, Marinovic J, Gutterman DD, Rakic M, Bosnjak ZJ, Stadnicka A,. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology 2008; 108: 612-620.
36. Wang C, Chiari PC, Weihrauch D, Krolikowski JG, Warltier DC, Kersten JR, Pratt PF Jr,. Pagel PS: gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. Anesth Analg 2006; 103: 274-280.
37. Tanaka K, Kehl F, Gu W, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR,. Isoflurane-induced preconditioning is attenuated by diabetes. Am J Physiol Heart Circ Physiol 2002; 282: H2018-2023.
38. Jonassen AK, Sack MN, Mjos OD, Yellon DM,. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001; 89: 1191-1198.
39. Rivo J, Raphael J, Drenger B, Berenshtein E, Chevion M, Gozal Y,. Flumazenil mimics whereas midazolam abolishes ischemic preconditioning in a rabbit heart model of ischemia-reperfusion. Anesthesiology 2006; 105: 65-71.
40. Hellström J, Ãwall A, Bergström J, Sackey PV,. Cardiac outcome after sevoflurane versus propofol sedation following coronary bypass surgery: a pilot study. Acta Anaesthesiol Scand 2011; 55: 460-467.